201 related articles for article (PubMed ID: 23729401)
1. Cyclooxygenase-2, epidermal growth factor receptor, and aromatase signaling in inflammation and mesothelioma.
Nuvoli B; Galati R
Mol Cancer Ther; 2013 Jun; 12(6):844-52. PubMed ID: 23729401
[TBL] [Abstract][Full Text] [Related]
2. Differential Susceptibility of Human Pleural and Peritoneal Mesothelial Cells to Asbestos Exposure.
Dragon J; Thompson J; MacPherson M; Shukla A
J Cell Biochem; 2015 Aug; 116(8):1540-52. PubMed ID: 25757056
[TBL] [Abstract][Full Text] [Related]
3. Gene-asbestos interaction in malignant pleural mesothelioma susceptibility.
Tunesi S; Ferrante D; Mirabelli D; Andorno S; Betti M; Fiorito G; Guarrera S; Casalone E; Neri M; Ugolini D; Bonassi S; Matullo G; Dianzani I; Magnani C
Carcinogenesis; 2015 Oct; 36(10):1129-35. PubMed ID: 26139392
[TBL] [Abstract][Full Text] [Related]
4. Malignant mesothelioma: development to therapy.
Thompson JK; Westbom CM; Shukla A
J Cell Biochem; 2014 Jan; 115(1):1-7. PubMed ID: 23959774
[TBL] [Abstract][Full Text] [Related]
5. Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy?
Signorelli D; Macerelli M; Proto C; Vitali M; Cona MS; Agustoni F; Zilembo N; Platania M; Trama A; Gallucci R; Ganzinelli M; Pelosi G; Pastorino U; de Braud F; Garassino MC; Lo Russo G
Tumori; 2016; 102(1):18-30. PubMed ID: 26481865
[TBL] [Abstract][Full Text] [Related]
6. Malignant Mesothelioma and Its Non-Asbestos Causes.
Attanoos RL; Churg A; Galateau-Salle F; Gibbs AR; Roggli VL
Arch Pathol Lab Med; 2018 Jun; 142(6):753-760. PubMed ID: 29480760
[TBL] [Abstract][Full Text] [Related]
7. Five years update on relationships between malignant pleural mesothelioma and exposure to asbestos and other elongated mineral particles.
Andujar P; Lacourt A; Brochard P; Pairon JC; Jaurand MC; Jean D
J Toxicol Environ Health B Crit Rev; 2016; 19(5-6):151-172. PubMed ID: 27705546
[TBL] [Abstract][Full Text] [Related]
8. An asbestos-exposed family with multiple cases of pleural malignant mesothelioma without inheritance of a predisposing BAP1 mutation.
Cheung M; Kadariya Y; Pei J; Talarchek J; Facciolo F; Visca P; Righi L; Cozzi I; Testa JR; Ascoli V
Cancer Genet; 2015 Oct; 208(10):502-7. PubMed ID: 26364129
[TBL] [Abstract][Full Text] [Related]
9. Comparative proteomic analysis of malignant pleural mesothelioma evidences an altered expression of nuclear lamin and filament-related proteins.
Giusti L; Da Valle Y; Bonotti A; Donadio E; Ciregia F; Ventroni T; Foddis R; Giannaccini G; Guglielmi G; Cristaudo A; Lucacchini A
Proteomics Clin Appl; 2014 Apr; 8(3-4):258-68. PubMed ID: 24415579
[TBL] [Abstract][Full Text] [Related]
10. Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma.
Andujar P; Pairon JC; Renier A; Descatha A; Hysi I; Abd-Alsamad I; Billon-Galland MA; Blons H; Clin B; Danel C; Debrosse D; Galateau-Sallé F; Housset B; Laurent-Puig P; Le Pimpec-Barthes F; Letourneux M; Monnet I; Régnard JF; Validire P; Zucman-Rossi J; Jaurand MC; Jean D
Mutagenesis; 2013 May; 28(3):323-31. PubMed ID: 23435014
[TBL] [Abstract][Full Text] [Related]
11. [Molecular heterogeneity of malignant pleural mesotheliomas].
Tranchant R; Montagne F; Jaurand MC; Jean D
Bull Cancer; 2018 Jan; 105(1):35-45. PubMed ID: 29277245
[TBL] [Abstract][Full Text] [Related]
12. Driver Gene and Novel Mutations in Asbestos-Exposed Lung Adenocarcinoma and Malignant Mesothelioma Detected by Exome Sequencing.
Mäki-Nevala S; Sarhadi VK; Knuuttila A; Scheinin I; Ellonen P; Lagström S; Rönty M; Kettunen E; Husgafvel-Pursiainen K; Wolff H; Knuutila S
Lung; 2016 Feb; 194(1):125-35. PubMed ID: 26463840
[TBL] [Abstract][Full Text] [Related]
13. Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies.
Bononi A; Napolitano A; Pass HI; Yang H; Carbone M
Expert Rev Respir Med; 2015 Oct; 9(5):633-54. PubMed ID: 26308799
[TBL] [Abstract][Full Text] [Related]
14. Intracavitary 'T4 immunotherapy' of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells.
Klampatsa A; Achkova DY; Davies DM; Parente-Pereira AC; Woodman N; Rosekilly J; Osborne G; Thayaparan T; Bille A; Sheaf M; Spicer JF; King J; Maher J
Cancer Lett; 2017 May; 393():52-59. PubMed ID: 28223167
[TBL] [Abstract][Full Text] [Related]
15. Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma.
Tsao A; Nakano T; Nowak AK; Popat S; Scagliotti GV; Heymach J
Semin Oncol; 2019 Apr; 46(2):145-154. PubMed ID: 31280996
[TBL] [Abstract][Full Text] [Related]
16. Inflammation-Related IL1β/IL1R Signaling Promotes the Development of Asbestos-Induced Malignant Mesothelioma.
Kadariya Y; Menges CW; Talarchek J; Cai KQ; Klein-Szanto AJ; Pietrofesa RA; Christofidou-Solomidou M; Cheung M; Mossman BT; Shukla A; Testa JR
Cancer Prev Res (Phila); 2016 May; 9(5):406-414. PubMed ID: 26935421
[TBL] [Abstract][Full Text] [Related]
17. Biological agents involved in malignant mesothelioma: relevance as biomarkers or therapeutic targets.
Crispi S; Cardillo I; Spugnini EP; Citro G; Menegozzo S; Baldi A
Curr Cancer Drug Targets; 2010 Feb; 10(1):19-26. PubMed ID: 20088796
[TBL] [Abstract][Full Text] [Related]
18. Implementation of a molecular epidemiology approach to human pleural malignant mesothelioma.
Puntoni R; Filiberti R; Cerrano PG; Neri M; Andreatta R; Bonassi S
Mutat Res; 2003 Nov; 544(2-3):385-96. PubMed ID: 14644341
[TBL] [Abstract][Full Text] [Related]
19. The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells.
Pattarozzi A; Carra E; Favoni RE; Würth R; Marubbi D; Filiberti RA; Mutti L; Florio T; Barbieri F; Daga A
Stem Cell Res Ther; 2017 May; 8(1):119. PubMed ID: 28545562
[TBL] [Abstract][Full Text] [Related]
20. Analysis of microRNA expression signatures in malignant pleural mesothelioma, pleural inflammation, and atypical mesothelial hyperplasia reveals common predictive tumorigenesis-related targets.
Ramírez-Salazar EG; Salinas-Silva LC; Vázquez-Manríquez ME; Gayosso-Gómez LV; Negrete-Garcia MC; Ramírez-Rodriguez SL; Chávez R; Zenteno E; Santillán P; Kelly-García J; Ortiz-Quintero B
Exp Mol Pathol; 2014 Dec; 97(3):375-85. PubMed ID: 25236577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]